Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The Landscape of Prostate Tumour Methylation.

Cancer discovery·2026
Same author

A Multidisciplinary Approach to Prevention and Treatment of Late Genitourinary Adverse Events After Radiotherapy for Prostate Cancer.

European urology·2026
Same author

NCCN Guidelines® Insights: Prostate Cancer, Version 5.2026.

Journal of the National Comprehensive Cancer Network : JNCCN·2026
Same author

Local Salvage Therapy Alone for Local Recurrence of Prostate Cancer After Radiotherapy: A Systematic Review and Meta-Analysis.

JAMA oncology·2026
Same author

Extended Follow-up from the Stereotactic Body Radiotherapy for High-risk Localized Carcinoma of the Prostate (SHARP) Consortium: Updated Analysis of 440 Patients.

European urology oncology·2026
Same author

Cost-effectiveness of an artificial intelligence predictive model for guiding androgen deprivation therapy in intermediate-risk prostate cancer.

JNCI cancer spectrum·2026
Same journal

Circulating Tumor DNA Status and Adjuvant Chemotherapy in Resected Colorectal Liver Metastases.

JAMA oncology·2026
Same journal

Cardiac Risk After Heart-Sparing Breast Radiotherapy.

JAMA oncology·2026
Same journal

When Not to Push the Boulder.

JAMA oncology·2026
Same journal

Circulating Methylated SEPT9 for Detection of Hepatocellular Carcinoma in Cirrhosis.

JAMA oncology·2026
Same journal

Less Can Be More by Circulating Tumor DNA Use in ERBB2-Positive Breast Cancer.

JAMA oncology·2026
Same journal

Long-Term Outcomes in Patients With Recurrent Ovarian Cancer and Exceptional Response to PARP Inhibitors.

JAMA oncology·2026
See all related articles

Related Experiment Video

Updated: May 16, 2025

Retzius-Sparing Robot-Assisted Radical Prostatectomy
12:10

Retzius-Sparing Robot-Assisted Radical Prostatectomy

Published on: May 19, 2022

7.4K

Patient-Reported Outcomes With Stereotactic Intensity Modulated Radiotherapy After Radical Prostatectomy: A

John Nikitas1,2, Leslie K Ballas3, Tahmineh Romero4

  • 1Department of Radiation Oncology, University of California, Los Angeles.

JAMA Oncology
|May 15, 2025
PubMed
Summary
This summary is machine-generated.

Stereotactic body radiotherapy (SBRT) after radical prostatectomy (RP) showed acceptable toxicity and similar patient-reported outcomes for urinary and bowel function compared to conventionally fractionated radiotherapy (CFRT). Further studies are needed to confirm efficacy and safety.

More Related Videos

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies
08:34

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies

Published on: February 6, 2019

20.1K
Stereotactic Radiosurgery for Gynecologic Cancer
10:35

Stereotactic Radiosurgery for Gynecologic Cancer

Published on: April 17, 2012

17.7K

Related Experiment Videos

Last Updated: May 16, 2025

Retzius-Sparing Robot-Assisted Radical Prostatectomy
12:10

Retzius-Sparing Robot-Assisted Radical Prostatectomy

Published on: May 19, 2022

7.4K
Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies
08:34

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies

Published on: February 6, 2019

20.1K
Stereotactic Radiosurgery for Gynecologic Cancer
10:35

Stereotactic Radiosurgery for Gynecologic Cancer

Published on: April 17, 2012

17.7K

Area of Science:

  • Oncology
  • Radiation Oncology
  • Urology

Background:

  • Postoperative radiotherapy is underutilized in men with biochemical recurrence or adverse pathological features after radical prostatectomy (RP).
  • Stereotactic body radiotherapy (SBRT) offers potential radiobiological advantages and may improve utilization for post-RP treatment.

Purpose of the Study:

  • To evaluate physician-reported late toxic effects following SBRT for men after RP.
  • To assess 2-year patient-reported outcomes (PROs) after SBRT in the post-RP setting.

Main Methods:

  • A phase 2, single-arm trial involving 100 men with post-RP prostate-specific antigen > 0.03 ng/mL or adverse pathologic features.
  • SBRT was delivered at 30-34 Gy in 5 fractions to the prostate bed; nodal irradiation and hormonal therapy were optional.
  • Late toxic effects were graded using CTCAE v4.03; PROs were measured using the Expanded Prostate Cancer Index-26 and compared to a conventionally fractionated radiotherapy (CFRT) cohort.

Main Results:

  • The cumulative incidence of late grade 2/3 genitourinary toxic effects was 25%/4%, and gastrointestinal toxic effects was 3%/3%.
  • At 2 years, 38.9% of patients had significant decrements in urinary incontinence PROs, 17.9% in urinary irritation, and 34.1% in bowel function.
  • Compared to CFRT, SBRT showed no statistically significant difference in the odds of experiencing decrements >2-fold the MCID for urinary incontinence (aOR 1.55), urinary irritation (aOR 0.94), or bowel function (aOR 1.03).

Conclusions:

  • Post-RP SBRT was well-tolerated in this nonrandomized trial.
  • Patient-reported urinary and bowel function outcomes at 2 years were not measurably different compared to CFRT.
  • Randomized trials and longer follow-up are necessary to fully define the toxic effects and efficacy of post-RP SBRT.